Specialty chemicals manufacturer Rossari Biotech Limited (Rossari) has announced its Consolidated financial results for the quarter ended June 30, 2025.

During Q1 FY26, Rossari’s consolidated revenue from operations grew 11 per cent to Rs. 543.7 crore as compared to Rs. 489.7 crore. EBITDA improved by 4.6 per cent to Rs. 67.9 crore from Rs. 64.9 crore. PAT reduced by 3.7 per cent to Rs. 33.6 crore from Rs. 34.9 crore.

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said: “We delivered a steady performance in Q1 FY26, with topline growth driven by strong momentum in our HPPC and AHN segments. Despite a challenging and evolving operating environment, our core businesses continued to demonstrate resilience. Though our export business was lower compared to the last quarter, it has shown healthy growth over the last year. While overall growth remained healthy, we are confident that our continued efficiency initiatives and focused efforts on optimising the product mix will continue to drive growth over the coming quarters.

The HPPC and AHN divisions achieved a healthy growth of 16% and 12% respectively, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. The HPPC segment remained the primary growth driver, supported by deeper market penetration and traction across agrochemicals, personal care, institutional and consumer business.

Our ongoing capacity expansion projects across verticals are progressing in a phased manner, with commissioning scheduled over the coming quarters. These strategic investments are aimed at enhancing manufacturing capabilities, improve supply chain agility, and strengthen our responsiveness to high-growth sectors such as personal care, agrochemicals, oil & gas and pharma. We believe these expansions will play a pivotal role in unlocking meaningful value and driving the next phase of ourgrowth journey.

Looking ahead, we remain committed to execution excellence, customer-led innovation, and sustainable value creation. Supported by a robust balance sheet, a strong R&D foundation, and our ongoing capacity expansion initiatives, we are well-positioned to navigate near-term challenges and deliver consistent, profitable growth for all stakeholders.”